Patents by Inventor Takako WILSON
Takako WILSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240327839Abstract: The present invention relates to novel compounds comprising novel delivery moieties for delivery of oligonucleotides, which are useful in the treatment of disease, suitably diseases of the liver.Type: ApplicationFiled: June 22, 2022Publication date: October 3, 2024Inventors: Patrick Joseph ANTONELLIS, Gregory Lawrence LACKNER, Takako WILSON
-
Publication number: 20240018182Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.Type: ApplicationFiled: September 8, 2023Publication date: January 18, 2024Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas MCMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
-
Patent number: 11787834Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.Type: GrantFiled: March 22, 2022Date of Patent: October 17, 2023Assignee: Eli Lilly and CompanyInventors: Adel Ahmed Rashad Ahmed, Joshua Ryan Clayton, Jose Eduardo Lopez, William Thomas McMillen, Ryan Edward Stites, Takako Wilson, Jacqueline Mary Wurst
-
Publication number: 20220324904Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.Type: ApplicationFiled: March 22, 2022Publication date: October 13, 2022Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas McMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
-
Patent number: 11167039Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.Type: GrantFiled: November 17, 2017Date of Patent: November 9, 2021Assignee: Eli Lilly and CompanyInventors: Yiqing Feng, Philip Arthur Hipskind, Renhua Li, Ling Liu, Takako Wilson, Aaron David Wrobleski
-
Publication number: 20200061204Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.Type: ApplicationFiled: November 17, 2017Publication date: February 27, 2020Inventors: Yiqing FENG, Philip Arthur HIPSKIND, Renhua LI, Ling LIU, Takako WILSON, Aaron David WROBLESKI
-
Patent number: 9000023Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: GrantFiled: August 21, 2012Date of Patent: April 7, 2015Assignee: Eli Lilly and CompanyInventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
-
Patent number: 8507490Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.Type: GrantFiled: November 5, 2009Date of Patent: August 13, 2013Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
-
Patent number: 8445493Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.Type: GrantFiled: November 9, 2009Date of Patent: May 21, 2013Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
-
Patent number: 8404687Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: GrantFiled: October 22, 2009Date of Patent: March 26, 2013Assignee: Eli Lilly and CompanyInventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)
-
Publication number: 20120316174Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: ApplicationFiled: August 21, 2012Publication date: December 13, 2012Applicant: ELI LILLY AND COMPANYInventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
-
Patent number: 8273742Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: GrantFiled: June 15, 2010Date of Patent: September 25, 2012Assignee: Eli Lilly and CompanyInventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
-
Publication number: 20110263602Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Applicant: ELI LILLY AND COMPANYInventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
-
Publication number: 20110190304Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: ApplicationFiled: October 22, 2009Publication date: August 4, 2011Applicant: ELI LILLY AND COMPANYInventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)
-
Publication number: 20110178093Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.Type: ApplicationFiled: November 9, 2009Publication date: July 21, 2011Applicant: ELI LILLY AND COMPANYInventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
-
Patent number: 7981892Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: GrantFiled: April 1, 2009Date of Patent: July 19, 2011Assignee: Eli Lilly and CompanyInventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
-
Publication number: 20110046143Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: ApplicationFiled: April 1, 2009Publication date: February 24, 2011Applicant: ELI LILLY AND COMPANYInventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
-
Publication number: 20100324048Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.Type: ApplicationFiled: June 15, 2010Publication date: December 23, 2010Applicant: ELI LILLY AND COMPANYInventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
